Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2008 | Other Grant/Funding Number | Ministry of Health |
Not provided
Not provided
recruitment difficulties
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of the study is to characterize the epidemiologic data of the neonatal and infant cholestasis.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| cholestasis | infant suffering from cholestasis proteomic urine analysis |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| proteomic urine analysis | Other | proteomic urine analysis |
|
| Measure | Description | Time Frame |
|---|---|---|
| Gathering mother epidemiologic characteristics as assessed by pregancy informations collection | Date of child birth, course of pregnancy, occurrence of twin pregnancy, serology abnormalities, family background of liver desease, course of previous pregnancies | Day 1 (inclusion) |
| Gathering new born epidemiologic characteristics as assessed by birth informations collection | Birth anamnesis, inclusion age, hepatic desease history, hemostasis workup, validated etiologic diagnosis and criteria for the diagnosis, specific and non-specific therapeutic care | Day 1 (inclusion) |
| Epidemiologic characteristics follow up as assessed by medical monitoring | Desease evolution in the first year of life, clinical evaluation, biological evaluation, final diagnosis, complications of the sickness, existence of transplatation, death | When children are between 12 and 18 months old |
| Measure | Description | Time Frame |
|---|---|---|
| Homogenization of diagnosis and treatment of new born with the constitution and follow up of a prospective cohorte | Homogenize the care pathway of neonatal and infant cholestasis | Up to 3 years |
| Extend the study to the national french territory using the hepatology association network |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
infant suffering from cholestasis
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pierre Broue, MD | UH Toulouse | Principal Investigator |
| Thierry Lamireau, MD | University Hospital, Bordeaux | Principal Investigator |
| Jane Languepin, MD | UH Limoges | Principal Investigator |
| Sebastien Fournier-Favre, MD | UH Monptellier | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UH Bordeaux | Bordeaux | France | ||||
| UH Limoges |
Not provided
| ID | Term |
|---|---|
| D002779 | Cholestasis |
| ID | Term |
|---|---|
| D001649 | Bile Duct Diseases |
| D001660 | Biliary Tract Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
proteomic urine analysis
Use this study to start a national study |
| Up to 3 years |
| Identification of proteomic profiles using the biologic collection gathered in the cohorte population | Identify one or more specific proteomic profile of neonatal cholestasis | Up to 3 years |
| Limoges |
| France |
| UH Montpellier | Montpellier | 34000 | France |
| UH Toulouse | Toulouse | 31000 | France |